Should You Invest in Celestica (CLS) Based on Bullish Wall Street Views?
Werte in diesem Artikel
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Celestica (CLS) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Celestica currently has an average brokerage recommendation (ABR) of 1.44, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by nine brokerage firms. An ABR of 1.44 approximates between Strong Buy and Buy.Of the nine recommendations that derive the current ABR, six are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.7% and 22.2% of all recommendations.Brokerage Recommendation Trends for CLSCheck price target & stock forecast for Celestica here>>>The ABR suggests buying Celestica, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.Zacks Rank Should Not Be Confused With ABRIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.Is CLS a Good Investment?In terms of earnings estimate revisions for Celestica, the Zacks Consensus Estimate for the current year has increased 0.8% over the past month to $4.78.Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Celestica. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Therefore, the Buy-equivalent ABR for Celestica may serve as a useful guide for investors.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Celestica, Inc. (CLS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Quelle: Zacks
Nachrichten zu Celestica Inc. (Sub Voting)
Analysen zu Celestica Inc. (Sub Voting)
Datum | Rating | Analyst | |
---|---|---|---|
17.08.2017 | Celestica Buy | Standpoint Research | |
27.01.2017 | Celestica Hold | Stifel, Nicolaus & Co., Inc. | |
18.11.2016 | Celestica Hold | Standpoint Research | |
15.01.2016 | Celestica Sector Perform | RBC Capital Markets | |
30.10.2015 | Celestica Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
17.08.2017 | Celestica Buy | Standpoint Research | |
27.01.2017 | Celestica Hold | Stifel, Nicolaus & Co., Inc. | |
30.10.2014 | Celestica Buy | Standpoint Research | |
25.10.2012 | Celestica buy | Paradigm Capital | |
17.10.2012 | Celestica sector outperform | Scotia Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
18.11.2016 | Celestica Hold | Standpoint Research | |
15.01.2016 | Celestica Sector Perform | RBC Capital Markets | |
30.10.2015 | Celestica Sector Perform | RBC Capital Markets | |
21.10.2015 | Celestica Sector Perform | RBC Capital Markets | |
07.12.2012 | Celestica sector perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
20.06.2011 | Celestica sell | Citigroup Corp. | |
22.02.2007 | Celestica reduce | UBS | |
22.07.2005 | Update Celestica Inc. (Sub Voting): Underperform | Bear Stearns |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Celestica Inc. (Sub Voting) nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen